Mowery & Schoenfeld Wealth Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Mowery & Schoenfeld Wealth Management’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.99K	Hold	4	–	–	﹤0.01%	329
2026 Q1	$1.79K	Sell	4 -17	-81%	-$7.93K	﹤0.01%	322
2025 Q4	$9.52K	Buy	21 +17	+425%	+$7.33K	0.01%	251
2025 Q3	$1.57K	Hold	4	–	–	﹤0.01%	342
2025 Q2	$1.78K	Hold	4	–	–	﹤0.01%	333
2025 Q1	$1.94K	Hold	4	–	–	﹤0.01%	389
2024 Q4	$1.61K	Buy	+4	New	+$1.85K	﹤0.01%	416

Other funds holding VRTX

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Mowery & Schoenfeld Wealth Management's VRTX Position: Q2 2026 in Review

Mowery & Schoenfeld Wealth Management held its Vertex Pharmaceuticals (VRTX) position steady in Q2 2026 at 4 shares worth $1.99K. The position accounts for ﹤0.01% of the portfolio, ranked #329.

Mowery & Schoenfeld Wealth Management first reported a position in VRTX in Q4 2024 and has held it in 7 quarters since. The position peaked at $9.52K in Q4 2025. 1,762 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

Mowery & Schoenfeld Wealth Management held 4 shares of Vertex Pharmaceuticals worth $1.99K as of Q2 2026.
Mowery & Schoenfeld Wealth Management left its Vertex Pharmaceuticals share count unchanged in Q2 2026.
Vertex Pharmaceuticals made up ﹤0.01% of Mowery & Schoenfeld Wealth Management's portfolio in Q2 2026, its #329 holding.
Mowery & Schoenfeld Wealth Management first reported a position in Vertex Pharmaceuticals in Q4 2024 and has held it in 7 quarters since.
Mowery & Schoenfeld Wealth Management's Vertex Pharmaceuticals position peaked at $9.52K in Q4 2025.
1,762 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Mowery & Schoenfeld Wealth Management's 13F filing for Q2 2026, filed 6 Aug 2026.